Tylenol leads the pain relief market

Geworin sales have increased 25% in 4 years, but the gap with the leader still remains

EZN, Taksen & Champ vs Maxibufen, Penzal & Brufen

Tyreno made the most sales in the antipyretic analgesic market last year.

 

Tylenol 8hrs ER performed poorly due to safety controversy, but overall brand sales increased slightly as Tylenol sold more.

 

Geworin, the second-largest product, has grown significantly in the last five years.

 

However, the sales gap between the 1st and 2nd places is unlikely to narrow.

 

2018~2019 Sales Change of Major Antipyretic Analgesic Brands (Unit: ₩100 Million, Source: IQVIA)

◆Tylenol ranks first with ₩29.8 billion Tylenol 8hrs ER's sales impact was minimal. According to drug research institute IQVIA on the 5th, Janssen's Tylenol series posted sales of ₩29.8 billion last year.

 

It is up 5.8% from 2018's ₩28.2 billion.

 

Expanding the scope to the past five years, the increase is 7.8% from ₩27.7 billion in 2015.

 

The change in sales of individual items is very interesting.

 

The two flagship products, Tylenol and Tylenol 8hrs ER , are plotting opposite sales figures.

 

First, Tylenol tablets are steadily increasing.

 

The company recorded ₩11.7 billion in 2015, ₩12.3 billion in 2016, ₩13.1 billion in 2017, ₩14.5 billion in 2018, and ₩18.3 billion in 2019.

 

On the other hand, Tylenol 8-hour ER is showing signs of slowing.

 

The figure is decreasing every year, including ₩13.8 billion in 2015, ₩13.3 billion in 2016, ₩12.9 billion in 2017, ₩10.8 billion in 2018, and ₩8.5 billion in 2019.

 

In 4 years, it has dropped 38.0%.

 

Sales changes of Tylenol and Tylenol 8hrs ER in the last five years (Unit: ₩100 Million, Source IQVIA)

This is attributed to the safety controversy of Tylenol 8 hour ER.

 

This product has been constantly worried about liver damage caused by misuse.

 

As a result, the Ministry of Food and Drug Safety implemented measures to strengthen safety in 2018.

 

In the process, the Tylenol ER was renamed Tylenol 8hrs ER .

 

In addition to Tylenol 8hrs ER, other slow-release tablets are observed to be on a similar path.

 

Since 2015, Penzal's 8-hour ER has decreased by 19.3% and Maxibufen ER by 23.0%.

 

◆Geworin 25% increase over 4 years Samjin's flagship product, Geworin was followed.

 

Geworin's revenue last year was ₩15.2 billion, up 9.7% from ₩13.8 billion in 2018.

 

This is an increase of 25.1% compared to 2015, five years ago.

 

However, the gap between the 1st and the 2nd places did not seem to narrow.

 

The gap between Tylenol and Geworin remains around ₩15 billion, including ₩15.6 billion in 2015, ₩14.2 billion in 2016, ₩16 billion in 2017, ₩14.4 billion in 2018, and ₩14.7 billion in 2019.

 

Sales changes of major antipyretic analgesic brands in recent 5 years (Unit: ₩100 Million, Source IQVIA)

Third place was Hanmi’s Maxibufen.

 

Last year, it recorded sales of ₩7.5 billion.

 

It has been ranked third for five years in a row, but sales are on the decline.

 

Compared with 2015 (₩8.5 billion), it decreased 11.7%.

 

In addition to the Maxibu fen ER, the sales of Maxibufen are also on the decline.

 

Daewoong Pharm's EZN series ranked fourth with ₩6 billion.

 

Contrary to Maxibufen, the growth rate is steep.

 

It is up 82.5% from last year's ₩3.3 billion.

 

The ranking in the antipyretic analgesic market also jumped from eighth to fourth in the same period.

 

In addition, GC Pharma's Taksen (₩5.6 billion), Ildong’s Carol (₩5.5 billion), Chong Kun Dang’s Penzal (₩5.5 billion), Ahn-gook’s Anyfen (₩5.2 billion), Samil’s Brufen, and Dong-A’s Champ were in the top ten.

 

In addition to last year's rankings, the increase in sales over the last five years has increased for Tylenol, Geworin, EZN, Taksen, Carol, Champ, Advil, and Gnal-N.

 

In particular, growth of Champ (246.6%), Gnal-N(91.5%), and EZN (82.5%) is noticeable.

 

On the other hand, Maxibufen, Penzal, Anypen, Brufen, and Trisfen have generally lost sales.

 

The reduction ranged from a minimum of 1.5% to a maximum of 61.7%.